US CRO contracted by FDA to answer generics safety questions

US CRO contracted by FDA to answer generics safety questions
CRO Vince & Associated Clinical Research (VACR) has won a $5m grant to conduct bioequivalence studies for the US FDA.

Under the contract, Kansas-based VACR will compare generic drugs with innovator products with the initial focus being on anti-epileptic products.

The contract research organisations (CRO)'s president Brad Vince said that: “With this contract we will seek to investigate the bioequivalence of generic products that have resulted in reports of Adverse Events to the FDA​.”

He added that: “We are truly excited to partner with the FDA to help address agency concerns with product substitution issues​.”

Related topics Clinical Development Phase III-IV

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars